50%

ICM dose reduction

Our completed clinical study demonstrates that the quality reserve provided by our technology can be effectively converted to significant contrast media (50%) reduction in carotid angiography. This brings significant economical and health benefits - less adverse events, contrast induced nephropathy - to the patients and cost saving for the cath labs. The clinical study was published in the European Journal of Radiology Open.